Dr. Amy J. Xu, MD, PhD

Dr. Xu practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Xu's NPI, 1093128308, was assigned on June 4, 2014. Dr. Xu graduated from Harvard Medical School in 2014. Dr. Xu's New York license number on file is 281901.

Dr. Xu's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Xu's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Monmouth. Dmand AI also links Dr. Xu to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Xu practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Xu's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Xu is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Xu's licenses on file in 3 states: New York, New Jersey and Massachusetts.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, breast cancer radiation, cervical cancer radiation and pancreatic cancer radiation among the conditions Dr. Xu treats.

CMS data shows 721 Medicare services from Dr. Xu across 12 procedure codes in 2024, for 246 Medicare patients. Medicare paid $57,447 for them.

CMS counts 246 Medicare patients who saw Dr. Xu in 2024. The largest group is 65 to 74, with 120 patients. 75% of them have cancer, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Xu's median patient age at 66, with 78% women.

In 2024, Dr. Xu wrote 54 Medicare Part D claims for 30 patients. 93% of them were for generic drugs. CMS names the drug for 23 of them, across 1 drug with 11 or more claims each, at $402 in total drug cost. In 2023, CMS named 18 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Xu for performance year 2024, reported as part of a group. Dr. Xu accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Xu as offering telehealth.

Dmand AI links 22 papers to Dr. Xu, published from 2019 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, Cyclin-Dependent Kinase 4 and Feasibility Studies. Dr. Xu has published most often in Adv Radiat Oncol. Dr. Xu's most frequent co-authors are Simon Nicholas Powell, MD, PhD, Lior Z. Braunstein, MD and Atif J. Khan, MD.

CMS Open Payments shows 18 general payments to Dr. Xu from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 56% of the total. AstraZeneca Pharmaceuticals LP paid the most, $2,265.

Dr. Xu graduated from Harvard Medical School in 2014.

Dr. Xu is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.